#hematologicmalignancies
#Medsky🧪 #IDSky #immunosky #virosky #publichealth Individuals with #postcovid / #LongCOVID HZ ( #herpeszoster/ #shingles) had significantly higher risks of developing #hematologicmalignancies & infectious complications.
September 24, 2025 at 8:18 PM
#Medsky🧪 #IDsky #immunosky #oncosky #publichealth Among ICHs, those with #hematologicmalignancies, particularly #Bcell malignancies and those receiving B-cell depletingtherapies, as #monoclonal antibodies (mAbs) targeting the CD20 #antigen (anti-CD20)
September 9, 2025 at 6:31 AM
"I research #cancer because I saw how our observations + measurements of the biopsies from patients suffering from #hematologicmalignancies can inform bench research…”
-Dr. Mina Xu
yalecancercenter.org/news-article...
#NCRM25 #unitedbycancerresearch
@theaacr.bsky.social @yalepathology.bsky.social
May 28, 2025 at 1:58 PM
Structural Determinants of Chimeric Antigen Receptor Design

dl.begellhouse.com/journals/2ff...

#CARTcell #CancerImmunotherapy #HematologicMalignancies
July 2, 2026 at 4:30 PM
February 9, 2026 at 9:20 PM
We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.”
Submission deadline: 19 Feb 2027
buff.ly/xsqkygl
#AML #PrecisionOncology #HematologicMalignancies #MRD
May 12, 2026 at 7:01 AM
Call for papers: a new collection in Ther Adv Med Oncol focuses on immunotherapy for T‑cell malignancies, spanning checkpoint inhibition, ADCs, bispecifics, cellular therapies, biomarkers, and resistance mechanisms.
buff.ly/y2kbSVy
#HematologicMalignancies #Immunotherapy #TCellLymphoma
April 28, 2026 at 7:01 AM
This study shows that purinostat mesylate, a #HDAC inhibitor, has good efficacy & immune-modulating effects in #MultipleMyeloma & #lymphoma, highlighting its potential as an effective therapy for #HematologicMalignancies. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...
August 30, 2025 at 4:00 AM
April 4, 2026 at 8:54 PM
April 4, 2026 at 8:53 PM
An overview of #CARTcelltherapy, examining applications in #HematologicMalignancies and #SolidTumors, while highlighting ongoing trials and future directions for effective CAR-T therapies in #AML. @idibaps.bsky.social #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...
October 13, 2025 at 2:31 PM
Join the Best of Hematology and Breast Cancer 2025, #Tucson, where Dr. Sharad Khurana, Dr. Sima Ehsani, and other leading experts will explore the latest advancements in the diagnosis and management of #HematologicMalignancies and #BreastCancer.🚀 Register TODAY: buff.ly/mTTdmdo #Medsky
August 20, 2025 at 5:21 PM